is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. That was one of the key messages from SynBioBeta’s Synthetic Biology Biopharma Conference last month ...

R&D leaders grapple with decisions about programme ... For a typical portfolio of a leading pharmaceutical company, assuming a composition of 75% small molecules and 25% biologics distributed ...

R&D returns have declined to 1.9%, down from 10.1% in 2010, with the figures showing a steady decline. Pharma R&D productivity hits new low amid rising costs | pharmaphorum Skip to main content ...

In the 20th century, pharmaceutical manufacturers made massive R&D investments in a collective quest to discover the next generation of lifesaving medications. Among those innovations were birth ...

There are also smaller pharma R&D companies, which sometimes get acquired by larger firms if their work seems promising. Companies in these categories research, develop and bring to market drugs ...

However, fast-selling GLP-1 medications are also bringing more R&D energy back to the small molecule arena with wider patient pools. Amid this backdrop, here are the forces shaping pharma’s ...

as will aligning R&D, medical affairs, and commercial functions to ensure seamless execution across the value chain. In addition, pharmaceutical companies should focus on elevating business acumen ...

Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing. Fosun Pharma’s ...

Union Finance Minister Nirmala Sitharaman is all set to present the Budget for the financial year 2025-26 in parliament on ...

Pharmaceutical and hospital sector executives are requesting higher public healthcare spending, R&D incentives, and tax ...